Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Next Previous
X
Search
Trial Profile

A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 28 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zavegepant (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company; Pfizer

    • Most Recent Events

    • 01 May 2024 Status changed from active, no longer recruiting to discontinued. (Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.)
    • 20 Mar 2024 Planned End Date changed from 12 Mar 2024 to 20 Mar 2024.
    • 20 Mar 2024 Planned primary completion date changed from 12 Mar 2024 to 20 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top